Atnaujinkite slapukų nuostatas

Hodgkin Lymphoma: A Comprehensive Update on Diagnostics and Clinics 2011 ed. [Kietas viršelis]

Edited by , Edited by
  • Formatas: Hardback, 381 pages, aukštis x plotis: 260x193 mm, weight: 1029 g, 30 black & white illustrations, 47 colour illustrations, biography
  • Serija: Hematologic Malignancies
  • Išleidimo metai: 11-Oct-2010
  • Leidėjas: Springer-Verlag Berlin and Heidelberg GmbH & Co. K
  • ISBN-10: 3642127797
  • ISBN-13: 9783642127793
Kitos knygos pagal šią temą:
  • Formatas: Hardback, 381 pages, aukštis x plotis: 260x193 mm, weight: 1029 g, 30 black & white illustrations, 47 colour illustrations, biography
  • Serija: Hematologic Malignancies
  • Išleidimo metai: 11-Oct-2010
  • Leidėjas: Springer-Verlag Berlin and Heidelberg GmbH & Co. K
  • ISBN-10: 3642127797
  • ISBN-13: 9783642127793
Kitos knygos pagal šią temą:
This book provides a well-illustrated, comprehensive, and up-to-date account of Hodgkin lymphoma. Epidemiology, pathogenesis, and the role of the microenvironment are examined in detail. The initial clinical evaluation and use of staging systems are fully discussed, and prognostic factors are carefully considered. The various treatment options for first-line and relapsed Hodgkin lymphoma are presented, including the newly available treatments for recurrent disease and the management required in special clinical circumstances. Given the very high cure rates and the young age of many patients, there is an increasing need to develop better individually tailored treatment strategies that will help to avoid both early and late side-effects of treatment. Such strategies receive due attention, and clear guidance is provided on the handling of Hodgkin survivors. This book will be of great value to hematologists, oncologists, and all others with an interest in Hodgkin lymphoma.

This comprehensive and up-to-date account of Hodgkin lymphoma examines epidemiology, pathogenesis and the role of the microenvironment. Discussion includes treatment options for first-line and recurrent cases, and individually tailored treatment strategies.
Part I From Hodgkin's Disease to Hodgkin Lymphoma
1 Epidemiology
3(18)
Sally L. Glaser
Ellen T. Chang
Christina A. Clarke
Theresa H. Keegan
2 The Role of Viruses in the Genesis of Hodgkin Lymphoma
21(12)
Ruth F. Jarrett
3 Pathology and Molecular Pathology of Hodgkin Lymphoma
33(16)
Andreas Rosenwald
Ralf Kuppers
4 Microenvironment, Cross-Talk, and Immune Escape Mechanisms
49(16)
Lydia Visser
Anke van den Berg
Sibrand Poppema
Arjan Diepstra
Part II Diagnosis and Treatment
5 Clinical Evaluation
65(12)
Jim Armitage
Christian Gisselbrecht
6 Functional Imaging
77(20)
Martin Hutchings
Andrea Gallamini
7 Prognostic Factors
97(20)
Lena Specht
Dirk Hasenclever
8 Principles of Radiation Techniques in Hodgkin Lymphoma
117(24)
Joachim Yahalom
Richard T. Hoppe
9 Principles of Chemotherapy in Hodgkin Lymphoma
141(22)
Patrice Carde
Peter Johnson
10 Treatment of Early Favorable Hodgkin Lymphoma
163(20)
Elly Lugtenburg
Anton Hagenbeek
11 Treatment of Early Unfavorable HL
183(8)
John M.M. Raemaekers
Andreas Engert
12 Treatment of Advanced Stage Hodgkin Lymphoma
191(12)
Peter Borchmann
Volker Diehl
13 Relapsed and Refractory Hodgkin Lymphoma
203(8)
Andreas Josting
Philip J. Biermann
14 Pediatric Hodgkin Lymphoma
211(18)
Georgina Hall
Cindy Schwartz
Stephen Daw
Louis S. Constine
Part III Special Clinical Situations
15 Lymphocyte-Predominant Hodgkin Lymphoma
229(12)
Andreas Engert
Anas Younes
16 The Management of Hodgkin Lymphoma During Pregnancy
241(8)
Veronika Bachanova
Joseph M. Connors
17 The Management of HIV-Hodgkin Lymphoma
249(10)
Michele Spina
Umberto Tirelli
18 The Management of Elderly Patients with Hodgkin Lymphoma
259(14)
Peter Borchmann
Teresa Halbsguth
Stephen J. Proctor
19 Allogeneic Transplantation for Relapsed Hodgkin Lymphoma
273(10)
Anna Sureda
Stephen MacKinnon
20 New Agents for Patients with Hodgkin Lymphoma
283(14)
Anas Younes
Andreas Engert
Part IV Survivorship
21 Quality of Life in Hodgkin Lymphoma
297(8)
Hans-Henning Flechtner
Peter Borchmann
22 Second Malignancy Risk After Treatment of Hodgkin Lymphoma
305(28)
David C. Hodgson
Flora E. van Leeuwen
23 Cardiovascular and Pulmonary Late Effects
333(12)
Berthe M.P. Aleman
24 Gonadal Dysfunction and Fertility Preservation in Hodgkin Lymphoma Patients
345(12)
Karolin Behringer
Michael von Wolff
Graham M. Mead
Part V Future Prospects
25 What Will We Learn from Genomics and Proteomics in Hodgkin Lymphoma?
357(10)
Christian Steidl
Randy D. Gascoyne
26 Personalized Medicine in Hodgkin Lymphoma?
367(6)
Dennis A. Eichenauer
Andreas Engert
Index 373
Andreas Engert M.D. is Professor for Internal Medicine, Hematology and Oncology. He received his medical degree at the University of Hannover and had his medical training at the University of Hannover and the University Hospital of Cologne. Between 1988 and 1990 he worked at the Imperial Cancer Research Fund in London on new immunotherapeutic approaches for cancer. After returning to Cologne, he and his group focused on developing antibody-based immunotherapy for patients with malignant lymphoma resulting in a number of experimental phase I/II clinical trials. He finished his postdoctoral lecture qualification in 1995, was appointed consultant and became head of staff 1996. He was appointed coordinating editor of the Cochrane Hematological Malignancies Group (CHMG) and vice director of the Department for Hematology and Oncology in 2000. After Serving as Secretary of the German Hodgkin Study Group (GHSG) since 1999, Prof. Engert was elected GHSG chairman in 2007. For his scientific work, he has received numerous awards including the Ludwig-Heilmeyer-Medal, the Arthur-Pappenheim Award and the Research Award of the University of Cologne. The focus of his research for many years has been the development of targeted therapy to combat malignancy. Activities include constructs such as bispecific monoclonal antibodies, radioimmunoconjugates, humanized antibodies or immunoligands for diseases such as neuroblastoma, chronic lymphocytic, acute leukemias and malignant lymphoma. Prof. Engert treats patients with all malignancies and consults for lymphoma patients. In addition he is active in the field of evidence-based medicine as editor of the Cochrane Review Group for Hematological Malignancies (CHMG). The clinical focus of his work is the German Hodgkin Study Group (GHSG) with all of its different facets including planning and conducting clinical trials of all phases. The GHSG has conducted more than 20 randomized studies with more than 20.000 patients overall registered and is actively involved in a number of early clinical trials evaluating new drugs for patients with Hodgkin Lymphoma.